IMV Inc. (IMVIF)

Market Cap	15.00 -100.0%
Revenue (ttm)	n/a
Net Income	-37.99M
EPS	-4.55
Shares Out	14.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,020
Open	0.000001
Previous Close	n/a
Day's Range	0.000001 - 0.000001
52-Week Range	0.000001 - 0.0020
Beta	4,085.45
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About IMV Inc.

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 63
• Stock Exchange: OTCMKTS
• Ticker Symbol: IMVIF

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 6, 2026

Data Sources Report a data error